Separate and Combined Extrapancreatic Effects of GIP and GLP-1

Phase

N/A

Condition

Diabetes And Hypertension

Diabetes Mellitus, Type 2

Diabetes Mellitus Types I And Ii

Treatment

Intravenous Infusion

Clinical Study ID

NCT06895408

101292 (H-21035117)

Ages 30-75
All Genders

Study Summary

The two gut-derived hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are secreted from intestinal cells in relation to a meal and increase insulin secretion from the pancreas. The hormones also exert effects outside the pancreas, but especially for GIP, these are poorly investigated. Because of this, only GLP-1 based drugs (GLP-1 receptor agonists) are on the market for the treatment of type 2 diabetes and obesity. Nonetheless, a new drug is in clinical development: a combined GIP-GLP-1-receptor agonist (tirzepatide), which has shown better results than GLP-1 alone. The mechanism behind these impressive effects are unknown and in this study, the investigators will look into the exptrapancreatic effects of GIP and GLP-1, separate and combined and thus elucidate the mechanisms of action of this new drug class.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Total pancreatectomy
Caucasians between 30-75 years of age
Blood haemoglobin >7.0 mmol/l for males and >6.5 mmol/l for females

Exclusion

Exclusion Criteria:

Pancreatectomy within the last 3 months
Ongoing chemotherapy or chemotherapy within the last 3 months
Treatment with GLP-1 receptor agonists within the last 3 months
Renal impairment (estimated by estimated glomerular filtration rate (eGFR) <60ml/min/1.73 m2) and/or albuminuria
Calcium related disease, hypo-/hyperthyroidism
Known significant liver disease, plasma alanine aminotransferase (ALT) or aspartateaminotransferase (AST) ≥3 × normal value or INR (The international normalised ratiobased on prothrombin time) outside the normal range
Severe arteriosclerotic heart disease or heart failure (New York Heart Association (NYHA) group III or IV)
Pregnancy and/or breastfeeding
Use of more than 14 units of alcohol per week or abuse of narcotics
Any condition that the investigator feels would interfere with trial participation

Study Design